Neurocrine Biosciences Stock Intrinsic Value – NEUROCRINE BIOSCIENCES Reports 19.7% Increase in Total Revenue for FY2023 Q2

August 26, 2023

☀️Earnings Overview

On June 30 2023, NEUROCRINE BIOSCIENCES ($NASDAQ:NBIX) reported its FY2023 Q2 earnings results, showing a 19.7% increase in total revenue from the same period in the previous year, with USD 452.7 million. Net income also rose significantly from -16.9 million to 95.5 million.

Analysis – Neurocrine Biosciences Stock Intrinsic Value

GoodWhale has performed an analysis of Neurocrine Biosciences‘ fundamentals and determined that their intrinsic value of a share is around $129.1, as calculated by our proprietary Valuation Line. At its current market price of $103.4, the stock is undervalued by 19.9%. This suggests that investors could capture value by buying the stock at its current price and benefit from potential upside through capital appreciation. The value of Neurocrine Biosciences’ stock could also be further increased through the implementation of strategies such as increasing their efficiency or expanding their customer base. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Neurocrine Biosciences. More…

    Total Revenues Net Income Net Margin
    1.67k 176.4 13.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Neurocrine Biosciences. More…

    Operations Investing Financing
    296.2 -344.9 47.1
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Neurocrine Biosciences. More…

    Total Assets Total Liabilities Book Value Per Share
    2.61k 760.1 18.99
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Neurocrine Biosciences are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    18.5% -6.2% 14.3%
    FCF Margin ROE ROA
    16.8% 8.4% 5.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company’s main competitors are TherapeuticsMD Inc, Invion Ltd, and Evotec SE.

    – TherapeuticsMD Inc ($NASDAQ:TXMD)

    TherapeuticsMD Inc is a biopharmaceutical company that develops and commercializes products for patients in the United States. The company has a market cap of 63.15M as of 2022 and a return on equity of 7.51%. TherapeuticsMD Inc focuses on developing and commercializing products for the treatment of menopause, osteoporosis, and other hormone-related disorders. The company’s products include ANNOVERA, an estrogen therapy; IMVEXXY, a bio-identical 17P; and BIJUVA, a bio-identical 17P/E2 combination therapy. TherapeuticsMD Inc was founded in 2010 and is headquartered in Boca Raton, Florida.

    – Invion Ltd ($ASX:IVX)

    Invion Ltd is a pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of inflammatory diseases. The company has a market capitalization of $70.62 million and a return on equity of -7.31%. The company’s products include INV102, which is in clinical development for the treatment of asthma and chronic obstructive pulmonary disease, and INV103, which is in preclinical development for the treatment of psoriasis.

    – Evotec SE ($LTS:0IRF)

    Evotec SE is a German biotechnology company focused on drug discovery and development. It has a market cap of 3.19B as of 2022 and a return on equity of 2.04%. The company has a strong focus on neuroscience and has a number of products in clinical trials for conditions such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease.


    Investors in Neurocrine Biosciences should be encouraged by the company’s strong financial performance in the second quarter of 2023. Revenue increased 19.7%, while net income saw a remarkable turnaround, from a loss of -16.9 million to a gain of 95.5 million. These impressive figures indicate strong growth and suggest that investors should view Neurocrine Biosciences as a lucrative long-term investment opportunity.

    Recent Posts

    Leave a Comment